GSK shares were up 0.3% to 1,733.7p in early morning trading on Tuesday, following the company’s acquisition of US clinical-stage biopharmaceutical company, Affinivax. GSK is set to acquire 100% of outstanding Affinivax shares, and confirmed that it would pay $2.1 billion immediately, and up to $1.2 billion in potential paediatric developmental milestones in separate payments […]

The post GSK acquires biopharma group Affinivax for $3.3bn appeared first on UK Investor Magazine.

Synairgen shares plummeted 23.6% to 26.6p in late afternoon trading on Wednesday, after the company reported a research and development tax credit uptick to £9.2 million from £3.8 million, leading to a post-tax loss of £48.7 million in FY 2021 compared to £13.9 million in FY 2020. The pharmaceutical group announced a £57.9 million loss […]

The post Synairgen shares plummet on Covid-19 drug stumble appeared first on UK Investor Magazine.

ImmuPharma shares were down 6.4% to 5.5p in early afternoon trading on Wednesday, after the group reported a widened loss to £8.2 million in its FY 2021 results, from a £6.9 million loss in FY 2020. The lupus-focused group confirmed research and development expenses of £3.7 million against £2.4 million the last year, along with […]

The post ImmuPharama shares fall on widened £8.2m loss appeared first on UK Investor Magazine.

AstraZeneca shares were up 0.4% to 10,553.6p in early morning trading on Thursday, following the firm’s announcement that its Ultomiris treatment had been approved in the US. The treatment was developed for adults with generalised myasthenia gravis (gMG), and is reportedly the first long-acting C5 complement inhibitor to demonstrate clinical improvement in patients with the […]

The post AstraZeneca treatment Ultomiris approved in US appeared first on UK Investor Magazine.

Hikma revenues grew 9% from $2.3bn to $2.5bn as core operating profit increased by 12% from $566m to $632m. The EPS remained unchanged and the reported profit which is distributed amongst the shareholders reduced by 2%. Dividend payout for the full year increased by 4 cents. Hikma Pharma also announced a change in their board […]

The post Hikma Pharmaceutical enjoys 9% revenue growth and strong momentum across the business appeared first on UK Investor Magazine.

Open Orphan (LON: ORPH) is planning to demerge a non-core asset inherited from the merger with hVIVO and not even mentioned in the merger document published at the end of 2019. There are other non-core assets that could be worth even more. Management of the contract research outfit wants to focus on the services business, […]

The post Non-core opportunities for Open Orphan appeared first on UK Investor Magazine.

Trading platform, IG Prime, published a white paper laying out the views of 253 hedge fund managers, on which sectors are most likely to grow over the next twelve months. Within the 41-page document, titled ‘Hedge fund trends: Covid-19 vs the global financial crisis’, 73% of those surveyed said that health and pharma will increase […]

The post Hedge fund managers are divided over an airline recovery in 2021 appeared first on UK Investor Magazine.

According to data compiled by ComprarAcciones, M&A deal activity in the pharma sector rose by 17% during the first half of 2020. To many, this would appear to be a positive shift, given the economic impacts of the pandemic. However, the rise in pharma industry deals might not come as a surprise to some, and […]

The post Pharma M&A deal value fell by more than 92% year-on-year appeared first on UK Investor Magazine.

Verona Pharma Plc (LON:VRP) have seen their shares crash 10% as the firm announced a couple of new senior management changes on Monday afternoon. Shares in Verona Pharma trade at 47p (-10.00%). 3/2/20 15:36BST. The firm said that former Dova Pharmaceuticals Inc boss David Zaccardelli had been appointed as president & chief executive officer. Notably, […]

The post Verona Pharma appoint new CEO and CFO appeared first on UK Investor Magazine.

Bermele (LON:BERM) is a standard list shell seeking to buy a pharma or biotechnology business. The focus is one or more businesses which have their own intellectual property. The areas that Bermele is assessing include diabetes, cancer and mental health. It is also looking at personalised medicine. Management will decide on which of these areas […]

The post Bermele seeks pharma acquisition appeared first on UK Investor Magazine.